BIOREDUCTIVELY ACTIVATED ANTITUMOR N-OXIDES: THE CASE OF AQ4N, A UNIQUE APPROACH TO HYPOXIA-ACTIVATED CANCER CHEMOTHERAPY

REFERENCES

• Brown J.M. Exploiting the Hypoxic Cancer Cell: Mechanisms and Therapeutic Strategies. Mol. Med. Today 2000; 6(4)157–162
   PubMedGoogle Scholar
• Gleadle J.M., Ratcliffe P.J. Hypoxia and the Regulation of Gene Expression. Mol. Med. Today 1998; 4: 122–129
   PubMedGoogle Scholar
• Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Loke S.W., Giaccia A.J. Hypoxia-Mediated Selection of Cells with Diminished Apoptotic Potential in Solid Tumors. Nature 1996; 379(6560)88–91
   PubMed Web of Science ®Google Scholar
• Adams G.E. Chemical Radiosensitization of Hypoxic Cells. Br. Med. Bull. 1973; 1: 48–53
   Google Scholar
• Wardman P. Electron Transfer and Oxidative Stress as Key Factors in the Design of Drugs Selectively Active in Hypoxia. Curr. Med. Chem. 2001; 8: 739–761
   PubMed Web of Science ®Google Scholar
• Overgaard J. Clinical Evaluation of Nitroimidazoles as Modifiers of Hypoxia in Solid Tumors. Oncol. Res. 1994; 6: 509–518
   PubMed Web of Science ®Google Scholar
• Workman P., Stratford I.J. The Experimental Development of Bioreductive Drugs and Their Role in Cancer Therapy. Cancer Metastasis Rev. 1993; 12: 73–82
   PubMed Web of Science ®Google Scholar
• Sartorelli A.C., Hodnick W.F., Belcourt M.F., Tomasz M., Haffty B., Fischer J.J., Rockwell S. Mitomycin C: A Prototype Bioreductive Agent. Oncol. Res. 1994; 6: 501–508
   PubMed Web of Science ®Google Scholar
• Verweij J., Aamdal S., Schellens J., Koier I., Lund B. Clinical Studies with EO9, a New Indoloquinone Bioreductive Alkylating Cytotoxic Agent. Oncol. Res. 1994; 6: 519–523
   PubMed Web of Science ®Google Scholar
• Maliepaard M., Wolfs A., Groot S.E., de Mol N.J., Janssen L.H.M. Indoloquinone EO9: DNA Interstrand Cross-Linking upon Reduction by DT-Diaphorase or Xanthine Oxidase. Br. J. Cancer 1995; 71: 836–839
   PubMed Web of Science ®Google Scholar
• Naylor M.A., Jaffar M., Nolan J., Stephens M.A., Butler S., Patel K.B., Everett S.A., Adams G.E., Stratford I.J. 2-Cyclopropylindoquinones and Their Analogues as Bioreductively Activated Antitumor Agents: Structure–Activity In Vitro and Efficacy In Vivo. J. Med. Chem. 1997; 40: 2335–2346
   PubMed Web of Science ®Google Scholar
• Brown J.M., Wang L.H. Tirapazamine: Laboratory Data Relevant to Clinical Activity. Anticancer Drug Des. 1998; 13: 529–539
   PubMedGoogle Scholar
• Daniels J.S., Gates K.S. DNA Cleavage by the Antitumor Agent 3-Amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233); Evidence for Involvement of Hydroxyl Radical. J. Am. Chem. Soc. 1996; 118: 3380–3385
   Web of Science ®Google Scholar
• Walton M.I., Workman P. Pharmacokinetics and Bioreductive Metabolism of the Novel Benzotriazine Di-N-oxide Hypoxic Cell Cytotoxin Tirapazamine (WIN 59075; SR4233; NSC 130181) in Mice. J. Pharmacol. Exp. Ther. 1993; 265: 938–947
   PubMed Web of Science ®Google Scholar
• Patterson L.H. Rationale for the Use of Aliphatic N-Oxides of Cytotoxic Anthraquinones as Prodrug DNA Binding Agents: A New Class of Bioreductive Drugs. Cancer Metastasis Rev. 1993; 12: 119–134
   PubMed Web of Science ®Google Scholar
• Patterson L.H., Craven M.R., Fisher G.R., Teesdale-Spittle P. Aliphatic Amine N-Oxides of DNA Binding Agents as Bioreductive Drugs. Oncol. Res. 1994; 6: 533–538
   PubMed Web of Science ®Google Scholar
• Smith P.J., Blunt J.N., Desnoyers R., Giles Y., Patterson L.H. DNA Topoisomerase II-Dependent Cytotoxicity of Alkylaminoanthraquinones and Their N-Oxides. Cancer Chemother. Pharmacol. 1997; 39: 455–461
   PubMed Web of Science ®Google Scholar
• Smith P.J., Desnoyers R., Blunt N., Giles Y., Patterson L.H., Watson J.V. Flow Cytometric Analysis and Confocal Imaging of Anticancer Alkylaminoanthraquinones and Their N-oxides in Intact Human Cells Using 647-nm Krypton Laser Excitation. Cytometry 1997; 27: 43–53
   PubMedGoogle Scholar
• Wilson W.R., Denny W.A., Pullen S.M., Thompson K.M., Patterson L.H., Li A.E. Tertiary Amine N-Oxides as Bioreductive Drugs: DACA N-Oxide, Nitracrine N-Oxide and AQ4N. Br. J. Cancer 1996; 74(Suppl. XXVII)S43–S47
   PubMedGoogle Scholar
• Patterson A.V., Saunders M.P., Chinje E.C., Patterson L.H., Stratford I.J. Enzymology of Tirapazamine Metabolism: A Review. Anti-cancer Drug Des. 1998; 13: 541–573
   PubMedGoogle Scholar
• Swaine D.J., Loadman P.M., Bibby M.C., Graham M.A., Patterson L.H. High Performance Liquid Chromatographic Analysis of AQ4N, an Alkylaminoanthraquinone N-Oxide. J. Chromatogr. 2000; 742: 239–245
   Web of Science ®Google Scholar
• Patterson L.H., McKeown S.R., Robson T., Gallagher R., Raleigh S.M., Orr S. Antitumor Prodrug Development Using Cytochrome P450 (CYP) Mediated Activation. Anti-cancer Drug Des. 1999; 14: 473–486
   PubMedGoogle Scholar
• Raleigh S.M., Wanogho E., Burke M.D., Patterson L.H. Rat Cytochromes P450 (CYP) Specifically Contribute to the Reductive Bioactivation of AQ4N, an Alkylaminoanthraquinone-di-N-oxide Anticancer Prodrug. Xenobiotica 1999; 29: 1115–1122
   PubMed Web of Science ®Google Scholar
• Raleigh S.M., Wanogho E., Burke M.D., McKeown S.R., Patterson L.H. Involvement of Human Cytochromes P450 (CYP) in the Reductive Metabolism of AQ4N, a Hypoxia Activated Anthraquinone di-N-oxide Prodrug. Int. J. Radiat. Oncol. Biol. Phys. 1998; 42: 763–767
   PubMed Web of Science ®Google Scholar
• Wrighton S.A., Schuetz E.G., Thummel K.E., Shen D.D., Korzekwa K.R., Watkins P.B. The Human CYP3A Subfamily: Practical Considerations. Drug Metab. Rev. 2000; 32(3-4)339–361
   PubMed Web of Science ®Google Scholar
• Thomsen L.L., Miles D.W. Role of Nitric Oxide in Tumor Progression: Lessons from Human Tumors. Cancer Metastasis Rev. 1998; 17: 107–118
   PubMed Web of Science ®Google Scholar
• Thomsen L.L., Miles D.W., Happerfield L., Bobrow L.G., Knowles R.G., Moncada S. Nitric Oxide Synthase Activity in Human Breast Cancer. Br. J. Cancer 1995; 72(1)41–44
   PubMed Web of Science ®Google Scholar
• Thomsen L.L., Lawton F.G., Knowles R.G., Beesley J.E., Riveros-Moreno V., Moncada S. Nitric Oxide Synthase Activity in Human Gynecological Cancer. Cancer Res. 1994; 54(5)1352–1354
   PubMed Web of Science ®Google Scholar
• Bickel, M. The Pharmacology and Biochemistry of N-Oxides. Pharmacology, 21 (), 325–355.
   Google Scholar
• Powis G., Wincenttsen L. Pyridine Nucleotide Cofactor Requirements of Indicine N-Oxide Reduction by Hepatic Microsomal Cytochrome P450. Biochem. Pharmacol. 1980; 29: 347–351
   PubMed Web of Science ®Google Scholar
• Kato R., Iwasaki K., Noguchi H. Reduction of Tertiary Amine N-Oxides by Cytochrome P450. Mechanism of the Stimulatory Effect of Flavins and Methyl Violgen. Mol. Pharmacol. 1978; 14: 654–664
   PubMed Web of Science ®Google Scholar
• Sugiura M., Iwasaki K., Kato R. Reduced Nicotinamide Adenine Dinucleotide-Dependent Reduction of Tertiary Amine N-Oxide by Liver Microsomal Cytochrome P450. Biochem. Pharmacol. 1977; 26: 489–495
   PubMed Web of Science ®Google Scholar
• Seto Y., Guengerich F.P. Partitioning Between N-Dealkylation and N-Oxygenation in the Oxidation of N,N-Dialkylarylamines Catalyzed by Cytochrome P2B1. J. Biol. Chem. 1993; 268: 9986–9997
   PubMed Web of Science ®Google Scholar
• McKeown S.R., Hejmadi M.V., McIntyre I.A., McAleer J.J.A., Patterson L.H. AQ4N: An Alkylaminoanthraquinone N-Oxide Showing Bioreductive Potential and Positive Interaction with Radiation In Vivo. Br. J. Cancer 1995; 72: 76–81
   PubMed Web of Science ®Google Scholar
• McKeown S.R., Friery O.P., McIntyre I.A., Hejmadi M.V., Hirst D.G., Patterson L.H., Hirst. Evidence of a Therapeutic Gain When AQ4N or Tirapazamine Is Combined with Radiation. Br. J. Cancer 1996; 74(Suppl. XXVII)S39–S42
   Google Scholar
• Patterson L.H., McKeown S.R., Ruparelia K., Double J.A., Bibby M.C., Cole S., Stratford I.J. Enhancement of Chemotherapy and Radiotherapy of Murine Tumors by AQ4N, a Bioreductively Activated Anti-tumor Agent. Br. J. Cancer 2000; 82(12)1984–1990
   PubMed Web of Science ®Google Scholar
• Hejmadi M.V., McKeown S.M., Friery O.P., McIntyre I.A., Patterson L.H., Hirst D.G. DNA Damage Following Combination of Radiation with the Bioreductive Drug AQ4N: Possible Selective Toxicity to Oxic and Hypoxic Cells. Br. J. Cancer 1996; 73: 499–505
   PubMed Web of Science ®Google Scholar
• McCarthy, H.O.; Hughes, C.; Keilty, G.; Murray, M.; Patterson, L.H.; Hirst, D.G.; McKeown, S.R.; Robson, T. Bioreductive GDEPT Using P4503A4 in Combination with AQ4N. Accepted for publication.
   Google Scholar
• Ueng Y.F., Kuwabara T., Chun Y.J., Guengerich F.P. Co-operativity in Oxidations Catalyzed by Cytochrome P450 3A4. Biochemistry 1997; 36: 370–381
   PubMed Web of Science ®Google Scholar
• Shou M., Lin Y., Lu P., Tang C., Mei Q., Cui D., Tang W., Ngui J.S., Lin C.C., Singh R., Wong B.K., Yergey J.A., Lin L.H., Pearson P.G., Baillie T.A., Rodrigues A.D., Rushmore T.H. Enzyme Kinetics of Cytochrome P450-Mediated Reaction. Curr. Drug Metab. 2001; 217–236
   Google Scholar
• De Groene E.M., Seinen W., Horbach G.J.M.J. A NIH/3T3 Cell-Line Stability Expressing Human Cytochrome P450/3A4 Used in Combination with a Lacz' Shuttle Vector to Study Mutagenicity. Eur. J. Pharmacol. 1995; 293: 47–53
   PubMed Web of Science ®Google Scholar
• Danesi R., De Braud F., Fogli S., Di Paolo A., Del Tacca M. Pharmacogenetic Determinants of Anti-cancer Drug Activity and Toxicity. Trends Pharmacol. Sci. 2001; 22: 420–426
   PubMed Web of Science ®Google Scholar
• Ingleman-Sundberg M. Duplication, Multiduplication, and Amplification of Genes Encoding Drug-Metabolizing Enzymes: Evolutionary, Toxicological, and Clinical Pharmacological Aspects. Drug Metab. Rev. 1999; 31: 339–459
   Google Scholar
• Kim I.H., Brown J.M. Reoxygentation and Rehypoxiation in the SCCVII Mouse-Tumor. Int. J. Radiat. Oncol. Biol. Phys. 1994; 29: 493–497
   PubMed Web of Science ®Google Scholar
• Raleigh S.M., Burke M.D., Murray G.I., Patterson L.H. Involvement of Renal Cell Carcinoma Cytochrome P450 in Bioreduction of AQ4N, a Hypoxic Tumor Activated Topoisomerase II Inhibitor. Ann. Oncol. 1996; 7(Suppl. 1)81
   Google Scholar
• Loadman P.M., Swaine D.J., Bibby M.C., Welham K.J., Patterson L.H. A Preclinical Pharmacokinetic Study of the Bioreductive Drug AQ4N. Drug Metab. Dispos. 2001; 29: 422–426
   PubMed Web of Science ®Google Scholar